Navigation Links
Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment

CHICAGO, Pharmion Corporation today released interim findings from its Phase II, multi-center clinical study of Amrubicin, the company's third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer.

These findings indicate favorable interim results in terms of response rate and safety when comparing Amrubicin to the current treatment standard, topotecan, in second-line treatment of platinum-sensitive small-cell lung cancer patients with extensive disease (ED-SCLC). The early results of this study were published online on the ASCO website during the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.

"Oncologists have very limited treatment options available for patients with extensive-disease small cell lung cancer, and regrettably, patients with this disease still have an exceptionally poor prognosis," said Andrew R. Allen, chief medical officer of Pharmion. "We are encouraged by these initial results which suggest Amrubicin's potential to improve the treatment landscape for small cell lung cancer."

The trial compares Amrubicin and topotecan in patients with ED-SCLC that initially responded to first-line platinum-based therapy but recurred or progressed at least 90 days after completion of first-line treatment. Study participants are randomized 2:1 to receive either Amrubicin (40 mg/m2 via 5- min.infusion daily x 3 days) or topotecan (1.5 mg/m2 via 30-min. infusion daily x 5 days), both starting on Day 1 of a 21-day cycle.

Response data from 24 evaluable patients have been analyzed, 15 treated with Amrubicin and nine with topotecan. Of the 15 Amrubicin patients, 40 percent showed an objective tumor response, including two complete responses and four partial responses. All responses are confirmed. None of the nine topotecan patients showed a response to the drug. The median duration of progression free survival at the interim analysis was 4.1 months for Amrubicin patients compared to 2.0 months for topotecan patients. Patients are being followed for overall survival.

Thirty patients in the trial were evaluable for toxicity and safety, 19 for Amrubicin and 11 for topotecan. The most common . grade 3 adverse events were hematological and were generally equal between the two arms. Cardiac adverse events were limited to tachycardia (< grade 3) for one Amrubicin and two topotecan patients. No anthracycline-induced cardiomyopathy has been observed to date.

"These results are extremely encouraging and entirely consistent with the data reported from Japanese studies," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study which will begin shortly for Amrubicin in second-line treatment of small cell lung cancer. "With no apparent difference in activity between Japanese and non-Japanese patients, Amrubicin may represent an important new treatment for this very difficult to treat disease."

Pharmion has two additional ongoing Phase 2 studies of Amrubicin therapy for small cell lung cancer patients; one as single-agent therapy in patients refractory to first-line therapy; and one as single-agent or combination therapy with cisplatin versus cisplatin plus etoposide in previously untreated extensive stage patients.


'"/>




Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. New Prostate Cancer Vaccine Shows Promise
3. Ebola Treatment Shows Promise
4. New Drug Shows Significant Improvement In HIV-related Heart Condition
5. Greek Study Shows Living In The Hills May Be Healthier
6. Research Shows Carbon Monoxide Prevents Inflammations
7. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
8. Novartis MS Drug Shows Promising Results
9. MRI Shows Emotional Changes During Menstrual Cycle
10. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia
11. AIDS drug GS 9137 Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
Breaking Medicine Technology: